Alternating versus sequential chemotherapy in small cell lung cancer. A randomized German multicenter trial

Area of Science:

• Oncology
• Medical Oncology
• Clinical Trials

Background:

• Small cell lung cancer (SCLC) remains a challenging diagnosis with limited treatment options.
• Optimizing chemotherapy delivery is crucial for improving patient outcomes in SCLC.

Purpose of the Study:

• To compare the efficacy and safety of sequential versus alternating chemotherapy regimens in patients with small cell lung cancer.
• To evaluate overall response rates, survival durations, and toxicity profiles between the two treatment arms.

Main Methods:

• A randomized trial involving 306 patients with SCLC, comparing sequential cyclophosphamide, Adriamycin, and vincristine (CAV) with an alternating regimen of etoposide, vindesine, ifosfamide (EVI), cisplatin, Adriamycin, vincristine (PAV), and cyclophosphamide, methotrexate, CCNU (CMC).
• Patients received prophylactic cranial and chest irradiation based on response.
• Minimum follow-up was 2 years for 302 evaluable patients.

Main Results:

• The alternating chemotherapy arm demonstrated a higher overall response rate (70%) compared to the sequential arm (59%).
• Complete response rates were significantly higher in the alternating arm (36%) versus sequential CAV (21%).
• Median survival and 2-year survival rates favored the alternating treatment for all patient groups (limited and extensive disease).

Conclusions:

• Alternating chemotherapy regimens are more effective than sequential application of CAV for treating SCLC.
• While alternating therapy shows superior efficacy, careful monitoring for increased toxicity is warranted.